Chemical Structure
Chemical Structure
PD 98,059 [167869-21-8]
AG-CR1-0118
CAS Number167869-21-8
Product group Chemicals
Estimated Purity>98% (NMR)
Molecular Weight267.3
Overview
- SupplierAdipoGen Life Sciences
- Product NamePD 98,059 [167869-21-8]
- Delivery Days Customer10
- CAS Number167869-21-8
- CertificationResearch Use Only
- Estimated Purity>98% (NMR)
- Hazard InformationNon-hazardous,Warning
- Molecular FormulaC16H13NO3
- Molecular Weight267.3
- Scientific DescriptionChemical. CAS: 167869-21-8. Formula: C16H13NO3. MW: 267.3. Highly selective, reversible and cell permeable MEK (MAP kinase kinase) inhibitor. Blocks the phosphorylation and activation of the MAP kinase pathway. T cell activation inhibitor. Inhibits cell growth and cell proliferation of several cancer cells. - Highly selective, reversible and cell permeable MEK (MAP kinase kinase) inhibitor [1-3, 7]. Blocks the phosphorylation and activation of the MAP kinase pathway [1-3, 7]. T cell activation inhibitor [4]. Inhibits cell growth and cell proliferation of several cancer cells [5, 6, 8].
- SMILESCOC1=C(N)C(=CC=C1)C1=CC(=O)C2=CC=CC=C2O1
- Storage Instruction2°C to 8°C,-20°C
- UNSPSC12352200
References
- A synthetic inhibitor of the mitogen-activated protein kinase cascade: D.T. Dudley, et al.; PNAS 92, 7686 (1995)
- Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor: L. Pang, et al.; J. Biol. Chem. 270, 13585 (1995)
- PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo: D. Alessi, et al.; J. Biol. Chem. 270, 27489 (1995)
- Inhibition of T cell activation by pharmacologic disruption of the MEK1/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production: F.J. Dumont, et al.; J. Immunol. 160, 2579 (1998)
- A phosphatidylinositol 3-kinase inhibitor induces a senescent-like growth arrest in human diploid fibroblasts: M. Tresini, et al.; Cancer Res. 58, 1 (1998)
- PD 098059, an inhibitor of ERK1 activation, attenuates the in vivo invasiveness of head and neck squamous cell carcinoma: C. Simon, et al.; Br. J. Cancer 80, 1412 (1999)
- Specificity and mechanism of action of some commonly used protein kinase inhibitors. S.P. Davies, et al.; Biochem. J. 351, 95 (2000)
- Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells: K. Kojima, et al.; Cancer Res. 67, 3210 (2007)